The probiotic Slab51 (Sivomixx®800, Ormendes, Switzerland) has been evaluated in sixty-nine adult COVID-19 patients with a confirmed diagnosis of SARS-CoV-2 related pneumonia a CT lung involvement greater than 50 percent and requiring non-invasive oxygen therapy. Patients supplemented with Slab51 in addition to standard therapy (n=40) showed significantly higher blood levels of partial pressure of oxygen (pO2), oxygenated hemoglobin (O2Hb), percentage of hemoglobin saturated with oxygen (SaO2), and a higher partial pressure of oxygen (pO2)/fraction of inspired oxygen (FiO2) ratio (pO2/ FiO2), than those on routine therapy alone (n=29). Results showed that patients on standard treatment had significantly higher oxygen requirements. One patient (2.5%) receiving Slab51, and four patients (13.8%) receiving only routine therapy, were transferred to intensive care.

This study confirms previous clinical studies and extends the knowledge on the mechanisms by which COVID 19-infected patients have a higher chance of survival and a reduced risk of respiratory failure when supplemented with Slab51(2, 3). This specific probiotic formulation modulates the blood consumption of oxygen in the gut making more oxygen available for critical organs (i.e. brain, heart, liver…). The “oxygen sparing effect” induced by Slab51 is also supported by in vitro experiments.

The unique property of the Slab51 probiotic formula opens a new promising scenario for the prevention and treatment of numerous health conditions where the need for oxygen is not fully satisfied. In this context, Slab51 could represent a safe add-on to the standard of care drugs for a wide spectrum of invalidating diseases such as chronic fatigue, neurodegenerative disorders, neonatal hypoxia and myocardial ischemia.

Pr De Simone, About

  1. Ceccarelli G. et al. Oxygen Sparing Effect of Bacteriotherapy in COVID-19 Nutrients 2021, 13(8), 2898;
  2. d’Ettorre G, Ceccarelli G, Marazzato M, Campagna G, Pinacchio C, Alessandri F, et al. Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. Front Med (Lausanne). 2020;7:389. 10.3389/fmed.2020.00389
  3. Ceccarelli G, Borrazzo C, Pinacchio C, Santinelli L, Innocenti GP, Cavallari EN, et al. Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study. Front Nutr. 2020;7:613928. 10.3389/fnut.2020.613928

Share this article!